Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Esflurbiprofen Patch vs Oral Flurbiprofen
NCT04505787Phase 1Completed
- Sponsor
- SocraTec R&D
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esflurbiprofen in pain, inflammation and osteoarthritis (OA) (2 arms), sponsored by SocraTec R&D. Primary endpoints: Area under the concentration-time curve over 24 hours at steady state and Maximum observed plasma concentration at steady state at 24 hours. Started Jul 2020; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
paininflammationosteoarthritis (OA)
Beyond the preview
Go deeper on NCT04505787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505787.